The first imitation in China! Zhengda sunny sunny benzostine through consistency evaluation

　　Pharmaceutical Network December 16th, December 11th, China Biopharmaceuticals announced that the subsidiary is Zhengda Tianqing Pharmaceutical Group's anti-tumor drug injection with hydrochloric acid benzostine has been issued by the State Drug Administration drug registration approval The product is in accordance with the new 3 categories of chemical declaration, as if through the quality and efficacy of generic drugs consistent evaluation, but also the first imitation approved Figure 1: Global sales of benzodiazepine hydrochloric acid source: Minet.com multinational listed company sales database
it is understood that benzodiazepine hydrochloric acid is a dual-functional alkyline, with anti-
and cell-killing effect Global sales of benzodiazepines in 2018 exceeded $600 million, according to Minenet notice that injection with benzodiazepine hydrochloride is suitable for the treatment of rituxicotributitributia or inthe treatment of bonotisxidine programme treatment or after treatment of the disease progression of the inert B-cell non-Hodgkin's lymphoma At present, only imported injection with benzodiazepine hydrochloride approved the listing, Zhengda Tianqing Pharmaceutical Group developed the injection of benzodiazepine spree market, will further enrich and improve the group's blood tumor product line layout According to the Minet MED China Review Database 2.0 data show that the three types of imitation listing applications for injection of benzodiazepines with hydrochloride, Sichuan Huiyu Pharmaceuticals, Jianjin Pharmaceuticals, Nanjing First Sound Dongyuan Pharmaceutical acceptance number in the review and approval sources: Company Announcement, Internet Database Review Data Statistics As of December 13, 2019